title: Meningococcal vaccines: Current state and future outlook.
abstract: Neisseria meningitidis infections are a major public health problem worldwide. Although conventional approaches have not led to development of a serogroup B meningococcal vaccine, a new technique based on genome sequencing has created new perspectives. Recently, a universal serogroup B meningococcal vaccine, Bexsero(®), was licensed in Europe, Australia and United States, following several clinical studies demonstrating its immunogenicity and safety. Availability of this vaccine could contribute positively to human health, by significantly reducing the incidence of meningococcal infections. However, unfavorable cost-effectiveness analysis means that routine vaccination is not currently recommended. Another serogroup meningococcal vaccine, Trumemba(®), was also recently licensed in United States. Like any drug, Bexsero(®) and Trumemba(®) will require close observation to assess their impact on meningococcal epidemiology.
authors.affiliation: Assistance Publique-Hôpitaux de Marseille (AP-HM), Pharmacie Usage Intérieur, Hôpital Nord, 13015 Marseille, France.
authors.forename: M
authors.initials: M
authors.lastname: Leca
authors.affiliation: Assistance Publique-Hôpitaux de Marseille (AP-HM), Pharmacie Usage Intérieur, Hôpital de la Conception, 13005 Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Bornet
authors.affiliation: Assistance Publique-Hôpitaux de Marseille (AP-HM), Oncopharma, 13005 Marseille, France; Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, 13005 Marseille, France.
authors.forename: M
authors.initials: M
authors.lastname: Montana
authors.affiliation: Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, 13005 Marseille, France; Assistance Publique-Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l'Information Pharmaceutiques (SCQIP), 13005 Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Curti
authors.affiliation: Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, 13005 Marseille, France; Assistance Publique-Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l'Information Pharmaceutiques (SCQIP), 13005 Marseille, France. Electronic address: patrice.vanelle@univ-amu.fr.
authors.forename: P
authors.initials: P
authors.lastname: Vanelle
mesh_terms: D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology; D001315:Australia; D016667:Bacterial Capsules / Q000235:genetics / Q000276:immunology; D003362:Cost-Benefit Analysis; D005060:Europe; D005544:Forecasting; D014943:Global Health; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000191:economics / Q000276:immunology; D009305:Nasopharynx / Q000382:microbiology; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology / Q000472:pathogenicity; D012641:Selection, Genetic; D014481:United States; D014611:Vaccination / Q000191:economics; D014774:Virulence
chemical_list: C570015:4CMenB vaccine; D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines
keywords: Bexsero(®); Neisseria meningitidis; Reverse vaccinology; Trumemba(®); Vaccin; Vaccine; Vaccinologie inverse